Puma Biotechnology, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Los Angeles CA United States (2007)

Organization Overview

First Clinical Trial
2007
NCT00146172
First Marketed Drug
2017
neratinib maleate (nerlynx)
First NDA Approval
2017
neratinib maleate (nerlynx)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

PUMA BIOTECH | Puma Biotechnology, Inc. | Ruth O'Regan